Synovetin OA® transforms the treatment of canine osteoarthritis1

Improves mobility so dogs can be life-loving pets again

Golden Retriever

Synovetin OA® is an effective new tool in treating canine elbow osteoarthritis (OA).

Just 1 minimally-invasive injection relieves pain and inflammation for up to 1 year2 

Synovetin OA™—Targets Synovial Inflammation1

icon dog

Restores active lifestyle

icon joint

Provides durable pain and inflammation relief

icon change

Alters the treatment of chronic OA

Synovetin OA

Effectiveness was demonstrated in a multi-center study2

Sites included Gulf Coast Veterinary Specialists, Louisiana State University School of Veterinary Medicine, and University of Missouri College of Veterinary Medicine.

3 validation metrics confirm formidable and durable treatment effect:

  • Effectiveness evaluated in Grade 1 & 2 and Grade 3 elbow OA
  • Dogs were given a single injection in 1 or 2 elbows and followed for 12 months
  • Study population included 69 dogs and 92 elbows

Images of synovitis and administration of Synovetin OA® are courtesy of Dr. Caleb Hudson, DVM, DACVS and Dr. Michelle Fabiani, DVM DACVR, Gulf Coast Veterinary Specialists


Synovetin OA® utilizes the procedure of Radio-Synovi-Orthesis (RSO) to break the cycle of inflammation and pain1

RSO is a well-established human procedure that has been successfully used for over 60 years3,4

The active agent of Synovetin OA® is Tin-117m, a unique conversion electron therapeutic veterinary device in an injectable colloidal suspension.1

Microparticles of Synovetin OA® selectively target the source of inflammatory mediators through dual cellular targeting (macrophages, activated synoviocytes)2,5

RSO in people3,4

Patients who have had RSO:
More than 670,000

Joints injected using RSO:
More than 830,000


40,000 to 50,000
procedures in Germany annually

Overall Treatment Success2*

Dogs with Grade 1 & 2 Elbow OA—


1 elbow treated; n=12/13

Dogs with Grade 3 Elbow OA—


Both elbows treated; n=10/14

*Overall treatment success based on a composite of force plate, Canine Brief Pain Inventory (CBPI), and clinician lameness assessments for the label dose.

Clinician’s lameness assessment—
Grade 1 & 2 Elbow OA

Dogs given the label dose had a mean reduction in overall lameness score from baseline at each post-treatment interval—1, 3, 6, 9, and 12 months2

9 to 12 months

Reductions in mean clinician’s lameness assessment scores for dogs with Grade 3 elbow OA were seen at 3, 6, and 9 months

Force plate gait analysis—Grade 1 & 2 Elbow OA

82% of dogs showed significant increase in peak vertical force and/or mean vertical impulse after just 1 injection.


Measurements taken at 1, 3, 6, 9, and 12 months.
Treatment Success = an improvement in PF and/or IMP during follow-up visit compared to baseline. n=22 dogs
PF=peak vertical force;
IMP=mean vertical impulse

jumping dog

Canine brief pain inventory instrument—Grade 1 & 2 and Grade 3 Elbow OA2

In Grade 1& 2 OA, mean PSS and PIS scores showed statistically significant improvement at all time intervals compared to baseline

There was statistical agreement between clinician and pet owner assessments.2

§ Brown D. Canine Brief Pain Inventory User Guide, 2017. No measurements were taken at Month 1 for Grade 3 elbow OA dogs.
PSS=pain severity score;
PIS=pain interference score
§Results at label dose


Synovetin OA® provides targeted, non-systemic therapy.1

Synovetin OA® answers a significant unmet need.


  1. Fox SM, Donecker JM. Synovitis. Technical Bulletin. Exubrion Therapeutics, July 2019.
  2. Data on File, Exubrion Therapeutics.
  3. Das BK. Role of radiosynovectomy in the treatment of rheumatoid arthritis and hemophilic arthropathies. Biomed Imaging Interv J. 2007;3(4):1-5. doi: 10.2349/biij.3.4.e45.
  4. Liepe K. 117mSn colloid in the radiosynovectomy. Presented at 2015 EANM, Hamburg, Germany, by Willem Uwe Kampen for the Bone and Joint Committee of EANM.
  5. Donecker JM, Stevenson NR. Radiosynoviorthesis: A new therapeutic and diagnostic tool for canine joint inflammation. Technical Bulletin. Exubrion Therapeutics, July 2019.